Gilead Sciences, Inc. and Nurix Therapeutics, Inc., entered a global strategic collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.   Under the multi-year collaboration, Nurix will utilize its drug discovery platform to identify novel agents that utilize E3 ligases to induce degradation of specified drug targets, and Gilead will have an option to license drug candidates directe...